

Long duration dual antiplatelet treatment increases bleeding

1 October 2015



More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

(HealthDay)—Routine use of dual antiplatelet therapy (DAPT) beyond six months after second generation drug-eluting stent (DES) implantation yields mixed clinical results, according to a review published in the October issue of *Cardiovascular Therapeutics*.

Elsayed Abo-salem, M.D., from the University of Cincinnati, and colleagues conducted a systematic literature search to identify <u>randomized controlled trials</u> (RCTs) comparing the continued use of DAPT with shorter duration of DAPT (aspirin alone) for variable durations beyond three months after DES implantation.

The researchers identified 10 RCTs with 32,136 subjects randomized to continued use of DAPT versus aspirin alone for variable durations after three months of DES implantation. The studies were not significant heterogeneously. Longer DAPT resulted in a significant reduction in <u>stent thrombosis</u> (P major bleeding (P

"DAPT continued beyond six months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)," the authors write.



APA citation: Long duration dual antiplatelet treatment increases bleeding (2015, October 1) retrieved 2 May 2021 from https://medicalxpress.com/news/2015-10-duration-dual-antiplatelet-treatment.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.